Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Fish and Richardson
Baxter
Boehringer Ingelheim
Fuji
Cipla
Citi
Cantor Fitzgerald
UBS
Harvard Business School

Generated: October 18, 2017

DrugPatentWatch Database Preview

NOVOLIN 70/30 Drug Profile

« Back to Dashboard

What is the patent landscape for Novolin 70/30, and what generic Novolin 70/30 alternatives are available?

Novolin 70/30 is a drug marketed by Novo Nordisk Inc and is included in two NDAs.

The generic ingredient in NOVOLIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are thirty-eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.

Summary for Tradename: NOVOLIN 70/30

US Patents:0
Applicants:1
NDAs:2
Suppliers / Packagers: see list4
Clinical Trials: see list10
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NOVOLIN 70/30 at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc
NOVOLIN 70/30
insulin recombinant purified human; insulin susp isophane semisynthetic purified human
INJECTABLE;INJECTION019441-001Jul 11, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Novo Nordisk Inc
NOVOLIN 70/30
insulin recombinant human; insulin susp isophane recombinant human
INJECTABLE;INJECTION019991-001Jun 25, 1991OTCYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Medtronic
Cantor Fitzgerald
UBS
Novartis
Healthtrust
Accenture
Cerilliant
Chinese Patent Office
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot